HCD’s health economists, market access and medical affairs specialists work hand in hand with our active network of global experts, clinicians and patients on specific diseases to provide the community with evidence for lobbying purposes and industry with a variety of services to support their own portfolio of therapies including:

  • Early product value assessment
  • Methodological and strategic advice
  • Organising and attending/chairing advisory boards
  • Review, critique and development of evidence generation plans
  • Review and critique of developed economic models and HTA evidence materials
  • Critical review of HTA submissions
  • Publications with accredited citable sources

HCD prides itself on ensuring that we combine the ability to shape and transform the pathway to reimbursement with post launch effectiveness.